Search research articles
Contact Us
Filters
Showing results (221-230 of 346) with videos related to
Page
of 35
Sort By:
Blood Advances
|
December 4, 2024
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy
Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, et al.
Journal of Hematology & Oncology
|
May 2, 2023
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
Hagop Kantarjian, Fadi G Haddad, Nitin Jain, et al.
Leukemia
|
April 13, 2021
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia
Guillermo Montalban-Bravo, Danielle Hammond, Courtney D DiNardo, et al.
Haematologica
|
October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor
Nicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
American Journal of Hematology
|
April 26, 2026
Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis
Elias Jabbour, Hannah Goulart, Koji Sasaki, et al.
American Journal of Hematology
|
July 29, 2023
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure
Samuel Urrutia, Kelly S Chien, Ziyi Li, et al.
American Journal of Hematology
|
January 4, 2022
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification
Patrick K Reville, Koji Sasaki, Hagop M Kantarjian, et al.
Blood Advances
|
April 27, 2023
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation
Nicholas J Short, Faustine Ong, Farhad Ravandi, et al.
JAMA Oncology
|
September 1, 2017
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial
Elias Jabbour, Farhad Ravandi, Partow Kebriaei, et al.
Leukemia & Lymphoma
|
June 10, 2024
<i>TP53</i> Y220C mutations in patients with myeloid malignancies
Georgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi, et al.
Page
of 35
Search research articles
Search
Showing results (221-230 of 346) with videos related to
Sort By:
Page
of 35
Blood Advances
|
December 4, 2024
Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy
Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, et al.
Journal of Hematology & Oncology
|
May 2, 2023
Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia
Hagop Kantarjian, Fadi G Haddad, Nitin Jain, et al.
Leukemia
|
April 13, 2021
Activity of venetoclax-based therapy in chronic myelomonocytic leukemia
Guillermo Montalban-Bravo, Danielle Hammond, Courtney D DiNardo, et al.
Haematologica
|
October 2, 2025
Long-term outcomes in FLT3-mutated acute myeloid leukemia after frontline hypomethylating agent, venetoclax and a FLT3 inhibitor
Nicholas J Short, Sanam Loghavi, Musa Yilmaz, et al.
American Journal of Hematology
|
April 26, 2026
Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis
Elias Jabbour, Hannah Goulart, Koji Sasaki, et al.
American Journal of Hematology
|
July 29, 2023
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure
Samuel Urrutia, Kelly S Chien, Ziyi Li, et al.
American Journal of Hematology
|
January 4, 2022
Improved outcomes among newly diagnosed patients with FMS-like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification
Patrick K Reville, Koji Sasaki, Hagop M Kantarjian, et al.
Blood Advances
|
April 27, 2023
Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation
Nicholas J Short, Faustine Ong, Farhad Ravandi, et al.
JAMA Oncology
|
September 1, 2017
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial
Elias Jabbour, Farhad Ravandi, Partow Kebriaei, et al.
Leukemia & Lymphoma
|
June 10, 2024
<i>TP53</i> Y220C mutations in patients with myeloid malignancies
Georgina Gener-Ricos, Jan P Bewersdorf, Sanam Loghavi, et al.
Page
of 35